… Human papillomavirus (HPV) 16 and 18 are the two most common HPV oncogenic types …
Lieu [64] estimated (based on existing knowledge about the vaccine at the time) that from the …

… vaccine for use in women and men up to age 45, and this article estimates the cost-effectiveness
of the vaccine … than forecasted by our model, mid-adult vaccination might yield greater …

… major impacts on the estimated cost-effectiveness of the vaccination strategies. However, …
almost universally found that the cost-effectiveness of HPV vaccination for adults aged 30 to 45 …

… This age group of girls was targeted because they are representative of the female population
prior to HPV exposure and thus are expected to benefit most from the vaccination. They …

… With respect to the primary prevention of HPV infection, it is expected that the 9vHPV
vaccine can reduce the lifetime risk of diagnosis with CC by an additional 10% in immunised …

… the transmission dynamics and the natural history of HPV infection and associated diseases
(cervical intraepithelial neoplasia, cervical cancer, and genital warts), we estimated the …

… We found that predicted health and cost-effectiveness outcomes for HPV9 are dependent
on the cervical-screening background, in which the factors include age range, screening …

… cost-effectiveness studies on the two-dose vaccine regimens to our knowledge. A national
HPV vaccination … studies in which the estimated benefit of vaccination is reduced as a result. …

… In addition, due to vaccine-induced herd effects, we estimated that 110 cases of cancer in …
additional benefits of boys’ vaccination into account, the overall ICER was estimated at €…

… benefits of a human papillomavirus (HPV) vaccination … estimated cost per QALY
gained by mid-adult vaccination across the 10,000 simulations and (2) constructing cost-effectiveness …